Bucci MP, Nassibi N, Gerard CL, Bui-Quoc E, Seassau M Immaturity of the oculomotor saccade and vergence interaction in dyslexic children: evidence from a reading and visual search study. PLoS One. 2012;7(3):e33458. doi: 10.1371/journal.pone.0033458. Epub 2012 Mar 16.
Eden GF, Stein JF, Wood HM, Wood FB Differences in eye movements and reading problems in dyslexic and normal children. Vision Res. 1994 May;34(10):1345-58.
Hutzler F, Wimmer H Eye movements of dyslexic children when reading in a regular orthography. Brain Lang. 2004 Apr;89(1):235-42.
Jainta S, Kapoula Z Dyslexic children are confronted with unstable binocular fixation while reading. PLoS One. 2011 Apr 6;6(4):e18694. doi: 10.1371/journal.pone.0018694.
McConkie GW, Kerr PW, Reddix MD, Zola D Eye movement control during reading: I. The location of initial eye fixations on words. Vision Res. 1988;28(10):1107-18.
Pavlidis GT Eye movement differences between dyslexics, normal, and retarded readers while sequentially fixating digits. Am J Optom Physiol Opt. 1985 Dec;62(12):820-32.
Prado C, Dubois M, Valdois S The eye movements of dyslexic children during reading and visual search: impact of the visual attention span. Vision Res. 2007 Sep;47(19):2521-30. Epub 2007 Aug 23.
Rounds BB, Manley CW, Norris RH The effect of oculomotor training on reading efficiency. J Am Optom Assoc. 1991 Feb;62(2):92-9.
Shainberg MJ Vision therapy and orthoptics. Am Orthopt J. 2010;60:28-32. Review.
Solan HA Deficient eye-movement patterns in achieving high school students: three case histories. J Learn Disabil. 1985 Feb;18(2):66-70.
Solan HA Eye movement problems in achieving readers: an update. Am J Optom Physiol Opt. 1985 Dec;62(12):812-9.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
